bioMerieux Reports Strong H1 2024 Growth

bioMerieux (FR:BIM) has released an update.

bioMerieux, a leader in in vitro diagnostics, reported a robust first-half of 2024 with a 9.9% organic sales growth to €1,902 million, and a significant 33% increase in net income compared to the previous year. The company’s strategic GO•28 plan and recent FDA approvals have propelled the growth, leading bioMerieux to raise its full-year guidance for both sales and CEBIT. The positive financial performance was partly offset by a negative currency impact.

For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.